Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02862457 | Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT02335411 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | completed | Phase 2 | 318 | Merck Sharp & Dohme LLCINDUSTRY | 0 |
| Aug 8, 2022 |
| clinicaltrials |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | completed | Phase 1 / Phase 2 | 184 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2022 | clinicaltrials |
| NCT00559182 | A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001) | completed | Phase 1 | 47 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 26, 2022 | clinicaltrials |
| NCT01567813 | Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070) | completed | — | 114,035 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 22, 2022 | clinicaltrials |
| NCT02255097 | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | completed | Phase 2 | 172 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2022 | clinicaltrials |
| NCT02142738 | Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | completed | Phase 3 | 305 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 13, 2022 | clinicaltrials |
| NCT02370498 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | completed | Phase 3 | 592 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 6, 2022 | clinicaltrials |
| NCT02674061 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | completed | Phase 2 | 376 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT03739138 | Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002) | terminated | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Feb 28, 2022 | clinicaltrials |
| NCT04859582 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT02555657 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | completed | Phase 3 | 622 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 10, 2021 | clinicaltrials |
| NCT03364049 | Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Nov 15, 2021 | clinicaltrials |
| NCT02576977 | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | terminated | Phase 3 | 251 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2021 | clinicaltrials |
| NCT01905657 | Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | completed | Phase 2 / Phase 3 | 1,034 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT02256436 | A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | completed | Phase 3 | 542 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 20, 2021 | clinicaltrials |
| NCT03317366 | Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies | no longer available | — | — | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 0 | Aug 6, 2021 | clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | terminated | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 20, 2021 | clinicaltrials |
| NCT01848834 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | completed | Phase 1 | 297 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2021 | clinicaltrials |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | completed | Phase 1 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT00773747 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | completed | Phase 3 | 637 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 30, 2021 | clinicaltrials |
| NCT00858234 | Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | completed | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 9, 2021 | clinicaltrials |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | terminated | Phase 1 | 77 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 8, 2021 | clinicaltrials |
| NCT00773838 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | completed | Phase 2 | 143 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT01178411 | An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | completed | Phase 1 / Phase 2 | 60 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 0 | Mar 10, 2021 | clinicaltrials |
| NCT03515824 | Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) | terminated | Phase 1 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Mar 9, 2021 | clinicaltrials |
| NCT02684617 | Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155) | terminated | Phase 1 | 75 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 1, 2021 | clinicaltrials |
| NCT01015131 | 18F-FLT-PET in Breast Cancer (MK-0000-139) | completed | Phase 2 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 11, 2021 | clinicaltrials |
| NCT02132754 | Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) | completed | Phase 1 | 116 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 28, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02447003 | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | completed | Phase 2 | 254 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 16, 2020 | clinicaltrials |
| NCT00642954 | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | completed | Phase 1 | 31 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 18, 2020 | clinicaltrials |
| NCT00128102 | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | completed | Phase 3 | 661 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 26, 2020 | clinicaltrials |
| NCT02476955 | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | terminated | Phase 1 | 41 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | completed | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 10, 2020 | clinicaltrials |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | terminated | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 16, 2020 | clinicaltrials |
| NCT03407170 | Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | terminated | Phase 2 | 1 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 15, 2020 | clinicaltrials |
| NCT01866319 | Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | completed | Phase 3 | 834 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 2, 2020 | clinicaltrials |
| NCT01704287 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | completed | Phase 2 | 540 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 18, 2020 | clinicaltrials |
| NCT02007070 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | completed | Phase 1 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 13, 2020 | clinicaltrials |
| NCT01609231 | A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) | terminated | Phase 2 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 4, 2020 | clinicaltrials |
| NCT01358331 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | terminated | Phase 1 | 25 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 2, 2020 | clinicaltrials |
| NCT02180061 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT03546842 | Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) | completed | Phase 3 | 201 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Feb 25, 2020 | clinicaltrials |
| NCT03881111 | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03326986 | Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001) | completed | Phase 1 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jan 9, 2020 | clinicaltrials |
| NCT01295827 | Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)(KEYNOTE-001) | completed | Phase 1 | 1,260 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 13, 2019 | clinicaltrials |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | completed | Phase 3 | 1,212 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) | terminated | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 14, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials